ArticleBMC health services research2022

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma.

Ting Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.